Last reviewed · How we verify
HIV therapy
ViiV Healthcare's HIV therapies work by inhibiting viral replication through various mechanisms including reverse transcriptase inhibition, protease inhibition, integrase inhibition, or entry inhibition, depending on the specific agent.
ViiV Healthcare's HIV therapies work by inhibiting viral replication through various mechanisms including reverse transcriptase inhibition, protease inhibition, integrase inhibition, or entry inhibition, depending on the specific agent. Used for HIV-1 infection (treatment and prevention), AIDS (acquired immunodeficiency syndrome).
At a glance
| Generic name | HIV therapy |
|---|---|
| Also known as | Selzentry, Celsentri |
| Sponsor | ViiV Healthcare |
| Drug class | Antiretroviral agents (multiple classes: NRTIs, NNRTIs, PIs, INSTIs, entry inhibitors) |
| Target | Multiple targets depending on specific agent (HIV reverse transcriptase, HIV protease, HIV integrase, CCR5 co-receptor, gp120/gp41 envelope proteins) |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease / Virology |
| Phase | FDA-approved |
Mechanism of action
ViiV Healthcare manufactures multiple HIV antiretroviral drugs across different drug classes. These agents target distinct steps in the HIV replication cycle: reverse transcriptase inhibitors block conversion of viral RNA to DNA, protease inhibitors prevent maturation of viral particles, integrase inhibitors block insertion of viral DNA into the host genome, and entry inhibitors prevent viral attachment or fusion with CD4+ T cells. Combination antiretroviral therapy (ART) using agents from multiple classes achieves viral suppression and immune reconstitution.
Approved indications
- HIV-1 infection (treatment and prevention)
- AIDS (acquired immunodeficiency syndrome)
Common side effects
- Nausea
- Diarrhea
- Headache
- Rash
- Lipodystrophy
- Hepatotoxicity
- Renal impairment
Key clinical trials
- MK-4646 Multiple Dose Trial in Participants With Human Immunodeficiency Virus Type 1 (HIV-1) (MK-4646-003) (PHASE1)
- Short-term Steroid Therapy in Patients With P. Jirovecii Pneumonia Due to HIV / AIDS (NA)
- Therapy Adapted for High Risk and Low Risk HIV-Associated Anal Cancer (PHASE2)
- TMC125-TiDP35-C239 - Continued Access to Etravirine (ETR) in Treatment Experienced HIV-1 Infected Participants (PHASE3)
- Lenacapavir Intensification to Disrupt HIV Reservoirs in Virologically Suppressed People With HIV Receiving Antiretroviral Therapy (PHASE1)
- Virotherapy and Natural History Study of KHSV-Associated Multricentric Castleman s Disease With Correlates of Disease Activity (PHASE2)
- Liver Fibrosis in HIV-Infected Patients With Elevated Liver Enzymes on Antiretroviral Therapy
- Opioid, HIV and Immune System (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- HIV therapy CI brief — competitive landscape report
- HIV therapy updates RSS · CI watch RSS
- ViiV Healthcare portfolio CI